东宝生物(300239) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥80,316,462.53, representing an 18.91% increase year-on-year[8] - Net profit attributable to shareholders decreased by 26.81% to ¥3,436,230.73 for the reporting period[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 14.91% to ¥2,635,901.21[8] - Basic earnings per share were ¥0.0075, down 26.47% compared to the same period last year[8] - The weighted average return on net assets was 0.48%, a decrease of 0.18% year-on-year[8] - Total operating revenue for the third quarter reached CNY 80,316,462.53, an increase from CNY 67,545,342.61 in the previous period, representing a growth of approximately 18.5%[51] - Net profit for the period was CNY 3,436,230.73, a decrease from CNY 4,694,768.29, reflecting a decline of approximately 26.8%[52] - Basic and diluted earnings per share decreased to CNY 0.0075 from CNY 0.0102, a decline of approximately 26.5%[53] - The total profit for the third quarter was approximately ¥18.52 million, an increase from ¥16.14 million in the same period last year, representing a growth of about 14.8%[64] - The net profit for the third quarter reached ¥15.68 million, compared to ¥13.69 million in the previous year, marking an increase of approximately 14.5%[64] - Basic and diluted earnings per share for the quarter were both ¥0.0340, up from ¥0.0297 in the same quarter last year, reflecting a growth of about 14.5%[64] Cash Flow and Liquidity - The net cash flow from operating activities showed a significant decline, with a net outflow of ¥24,456,863.38, a decrease of 316.46%[8] - Cash and cash equivalents decreased by 81.47%, from CNY 142,181,239.36 to CNY 26,349,299.05, primarily due to expenditures related to the Binhe New District project[19] - Cash flow from operating activities decreased by 93.03%, from CNY 13,125,018.26 to CNY 914,987.82, mainly due to the previous year's employee stock ownership plan receipts[22] - Cash inflow from operating activities totaled ¥121.94 million, a decrease from ¥132.13 million year-over-year, indicating a decline of approximately 7.5%[67] - Cash outflow from operating activities was ¥146.40 million, compared to ¥120.83 million in the previous year, representing an increase of about 21.2%[67] - The net cash flow from operating activities was negative at ¥24.46 million, contrasting with a positive cash flow of ¥11.30 million in the same quarter last year[67] - The ending cash and cash equivalents balance was ¥26.35 million, a significant decrease from ¥135.13 million at the end of the same quarter last year[68] Assets and Liabilities - Total assets at the end of the reporting period reached ¥878,931,471.15, an increase of 5.50% compared to the previous year[8] - Cash and cash equivalents decreased significantly to CNY 26,159,112.02 from CNY 142,134,000.94, a decline of about 81.6%[47] - Total liabilities increased by 59.83%, with accounts payable rising from CNY 75,353,510.84 to CNY 120,441,029.05, driven by increased construction costs and raw material procurement[20] - The total liabilities increased to CNY 155,964,176.40 from CNY 114,252,133.18, marking an increase of approximately 36.5%[49] - The company's total equity increased to CNY 737,265,605.39 from CNY 733,110,282.06, a slight increase of about 0.6%[49] Investments and Projects - The company plans to continue investing in the Binhe New District project and expects further increases in production capacity and operational efficiency in the upcoming quarters[19] - The company is actively developing new applications for gelatin in baking, meat products, and candies, expanding its market reach[29] - The company plans to officially launch its 3,500-ton new process gelatin project by the end of November, following the completion of necessary production permits[25] - The company is collaborating with the Institute of Physics, Chinese Academy of Sciences, to establish a collagen industry research institute, enhancing its technological capabilities[26] - The company is advancing its non-public stock issuance project to support the expansion of its gelatin production capacity from 3,500 tons to 7,000 tons annually[29] - The company has achieved significant progress in its R&D projects, including the development of medical collagen hydrolysate and bone collagen peptides, with plans for industrialization[30] - The company signed an exclusive agency agreement with Pureorg for collagen peptides in North America, indicating a strategic move to expand its international market presence[28] - The clinical research project on "Oral Collagen Peptide Combined with Calcium D for Osteoporosis Treatment" has entered the final application research stage, with promising results and related papers being drafted[31] - The company plans to increase its annual production capacity of gelatin from 3,500 tons to 7,000 tons and establish a 2,000-ton collagen protein project, with a total fundraising target of up to 365.27 million yuan[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,329[12] - The largest shareholder, Inner Mongolia Dongbao Trade Co., Ltd., held 32.36% of the shares, amounting to 149,143,800 shares[12] - The company’s cash dividend distribution for the 2016 fiscal year was 0.25 yuan per share, totaling 11.52 million yuan distributed to shareholders[37] - The company has no overdue commitments from controlling shareholders or related parties during the reporting period[35] Operational Costs - Operating costs amounted to CNY 77,174,472.95, up from CNY 64,742,599.45, indicating an increase of about 19.1%[51] - Total operating costs amounted to CNY 226,946,025.66, a rise of 3.5% from CNY 220,168,114.40 in the previous period[58] - Sales expenses decreased to CNY 11,344,132.29, down 22.5% from CNY 14,545,084.75 in the previous year[58] - Management expenses increased slightly to CNY 21,275,872.65, compared to CNY 20,916,033.49 in the previous period[58]